RemeGen’s telitacicept delivered a strong interim efficacy signal in a prespecified Phase 3 analysis in high-risk IgA nephropathy, according to results presented at NEJM.org and associated meeting presentations. In the trial of 318 adults with biopsy-proven IgA nephropathy and persistent proteinuria despite supportive care, telitacicept produced a substantially larger reduction in urinary protein-to-creatinine measures at 39 weeks than placebo. The geometric mean ratio of 24-hour protein-to-creatinine fell 58.9% with telitacicept versus 8.8% with placebo. Safety events were more frequent with telitacicept (89.3% vs 78.6%), though serious adverse events were less common than with placebo (2.5% vs 8.2%). No unexpected safety findings were reported, and estimated glomerular filtration rate changes favored telitacicept directionally at interim follow-up.